B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

Acalabrutinib

0 PubMed studies analyzed

Similar Compounds by Shared Targets

The following compounds share molecular targets with Acalabrutinib, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

zanubrutinib
11 shared targets
tirabrutinib
8 shared targets
ritlecitinib
8 shared targets
spebrutinib
7 shared targets
evobrutinib
6 shared targets
bdb
6 shared targets
ibrutinib
11 shared targets
dacomitinib
4 shared targets
tolebrutinib
3 shared targets
ac
3 shared targets
Loading evidence profile...

This evidence profile for Acalabrutinib is generated deterministically from 0 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: v20260227-01. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.